Clinical trial
Combination Therapy in Pulmonary Arterial Hypertension
NCT00433329 · Actelion, Industry · Completed
Key facts
| NCT number | NCT00433329 |
|---|---|
| Title | Combination Therapy in Pulmonary Arterial Hypertension |
| Official title | COMPASS 3: An Open-label, Multi-Center Study Employing a Targeted 6-Minute Walk Test (6-MWT) Distance Threshold Approach to Guide Bosentan-Based Therapy and to Assess the Utility of Magnetic Resonance Imaging (MRI) on Cardiac Remodeling |
| Acronym | COMPASS 3 |
| Lead sponsor | Actelion, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Pulmonary Arterial Hypertension |
| Intervention type | Drug |
| Interventions | Bosentan, Sildenafil |
| Enrollment | 100 |
| Start date | Mar 1, 2007 |
| Primary completion | May 1, 2010 |
| Completion | Aug 1, 2010 |
| First posted | Feb 9, 2007 |
| Last update posted | Feb 4, 2025 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: